News | December 01, 2023
Biocon Biologics completes Integration of Viatris' Biosimilar business
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
The full transition of Viatris' biosimilars operations to Biocon Biologics in Europe represents another significant milestone
The divestment is a part of Fortis' ongoing portfolio rationalization strategy
Laurus Labs concluded the acquisition by securing the remaining 8,333 equity shares from the promoter group shareholders
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Total transaction value of the divestment is Rs. 3,660 million
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
Investment is additive to KKR’s existing health care growth strategy
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Subscribe To Our Newsletter & Stay Updated
